The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global protein engineering market was valued at US$ 2.61 Billion in 2021.
We expect the global protein engineering market to exhibit a CAGR of 11.60% during 2022-2027.
The high prevalence of protein-deficient diseases, rising advancements in synthetic biology, and
improving focus towards protein-based drug development are primarily driving the global protein
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of protein
engineering process for manufacturing novel vaccines to treat the coronavirus-infected patients and
to prevent the risk of the infection.
Based on the product and services, the global protein engineering market has been divided into
instruments, reagents, and services and software. Currently, instruments exhibit a clear dominance
in the market.
Based on the protein type, the global protein engineering market can be categorized into insulin,
monoclonal antibodies, coagulation factors, vaccines, growth factors, and others. Among these,
monoclonal antibodies hold the majority of the total market share.
Based on the technology, the global protein engineering market has been segmented into irrational
protein design and rational protein design. Currently, rational protein design represents the largest
Based on the end user, the global protein engineering market can be bifurcated into pharmaceutical
and biotechnology companies, academic research institutes, and contract research organizations.
Among these, pharmaceutical and biotechnology companies currently account for the majority of
the total market share.
On a regional level, the market has been classified into North America, Europe, Asia-Pacific, Middle
East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global protein engineering market include Abzena Ltd., Agilent
Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher
Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S,
PerkinElmer Inc., Thermo Fisher Scientific Inc., and Waters Corporation.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at